Stockreport

Annexon: Maintaining "Buy" Rating On Second C1q Inhibitor Advancement For Geographic Atrophy [Seeking Alpha]

Annexon, Inc. - common stock  (ANNX) 
PDF ANNX advances tanruprubart for Guillain-Barré syndrome, with an EMA filing planned for January 2026 and ongoing FDA discussions. Vonaprument, targeting dry age-relate [Read more]